| International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ... The lancet oncology 15 (12), e538-e548, 2014 | 5139 | 2014 |
| Improved survival in multiple myeloma and the impact of novel therapies SK Kumar, SV Rajkumar, A Dispenzieri, MQ Lacy, SR Hayman, FK Buadi, ... Blood, The Journal of the American Society of Hematology 111 (5), 2516-2520, 2008 | 2809 | 2008 |
| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ... The lancet oncology 17 (8), e328-e346, 2016 | 2566 | 2016 |
| Revised international staging system for multiple myeloma: a report from International Myeloma Working Group A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, ... Journal of clinical oncology 33 (26), 2863-2869, 2015 | 2199 | 2015 |
| Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients SK Kumar, A Dispenzieri, MQ Lacy, MA Gertz, FK Buadi, S Pandey, ... Leukemia 28 (5), 1122-1128, 2014 | 1521 | 2014 |
| Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study O Landgren, RA Kyle, RM Pfeiffer, JA Katzmann, NE Caporaso, RB Hayes, ... Blood, The Journal of the American Society of Hematology 113 (22), 5412-5417, 2009 | 1407 | 2009 |
| Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma P Moreau, T Masszi, N Grzasko, NJ Bahlis, M Hansson, L Pour, I Sandhu, ... New England Journal of Medicine 374 (17), 1621-1634, 2016 | 1234 | 2016 |
| Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma JJ Keats, R Fonseca, M Chesi, R Schop, A Baker, WJ Chng, S Van Wier, ... Cancer cell 12 (2), 131-144, 2007 | 1229 | 2007 |
| Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements S Kumar, A Dispenzieri, MQ Lacy, SR Hayman, FK Buadi, C Colby, ... Journal of Clinical Oncology 30 (9), 989-995, 2012 | 1119 | 2012 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 958 | 2012 |
| New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes G Palladini, A Dispenzieri, MA Gertz, S Kumar, A Wechalekar, ... Journal of clinical oncology 30 (36), 4541-4549, 2012 | 948 | 2012 |
| Mesenteric venous thrombosis S Kumar, MG Sarr, PS Kamath New England Journal of Medicine 345 (23), 1683-1688, 2001 | 905 | 2001 |
| Daratumumab plus lenalidomide and dexamethasone for untreated myeloma T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... New England Journal of Medicine 380 (22), 2104-2115, 2019 | 895 | 2019 |
| Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma SV Rajkumar, SR Hayman, MQ Lacy, A Dispenzieri, SM Geyer, B Kabat, ... Blood 106 (13), 4050-4053, 2005 | 874 | 2005 |
| Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report A Palumbo, S Bringhen, MV Mateos, A Larocca, T Facon, SK Kumar, ... Blood, The Journal of the American Society of Hematology 125 (13), 2068-2074, 2015 | 784 | 2015 |
| Clonal competition with alternating dominance in multiple myeloma JJ Keats, M Chesi, JB Egan, VM Garbitt, SE Palmer, E Braggio, ... Blood, The Journal of the American Society of Hematology 120 (5), 1067-1076, 2012 | 783 | 2012 |
| The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ... Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022 | 762 | 2022 |
| Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013 JR Mikhael, D Dingli, V Roy, CB Reeder, FK Buadi, SR Hayman, ... Mayo Clinic Proceedings 88 (4), 360-376, 2013 | 692 | 2013 |
| Multiple myeloma: diagnosis and treatment SV Rajkumar, S Kumar Mayo Clinic Proceedings 91 (1), 101-119, 2016 | 662 | 2016 |
| Long-term follow-up of monoclonal gammopathy of undetermined significance RA Kyle, DR Larson, TM Therneau, A Dispenzieri, S Kumar, JR Cerhan, ... New England journal of medicine 378 (3), 241-249, 2018 | 586 | 2018 |
Angela DispenzieriMayo ClinicVerified email at mayo.edu